Generation Bio Co. Stock News

Metropolitan Life Insurance Co NY increased its stake in shares of Generation Bio Co. (NASDAQ:GBIO) by 108,836.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 11,983 shares of the company’s stock after purchasing an additional 11,972 shares during the period. Metropolitan Life Insurance Co NY’s holdings […]

Marshall Wace LLP bought a new position in Generation Bio Co. (NASDAQ:GBIO) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 111,330 shares of the companys stock, valued at approximately $2,995,000. Marshall Wace LLP owned approximately 0.20% of Generation Bio at the end of the most []

Zacks Investment Research upgraded shares of Generation Bio (NASDAQ:GBIO) from a sell rating to a hold rating in a research note released on Tuesday, Zacks.com reports. According to Zacks, Generation Bio Co. is a genetic medicines company. It is focused on creating gene therapy for patients suffering from both rare and prevalent diseases. Generation Bio []

Zacks Investment Research upgraded shares of Generation Bio (NASDAQ:GBIO) from a sell rating to a hold rating in a research report report published on Tuesday morning, Zacks.com reports. According to Zacks, Generation Bio Co. is a genetic medicines company. It is focused on creating gene therapy for patients suffering from both rare and prevalent diseases. []

Generation Bio Co. (NASDAQ:GBIO) Stock analysts at Jefferies Financial Group increased their FY2021 earnings per share (EPS) estimates for shares of Generation Bio in a research note issued to investors on Wednesday, November 10th. Jefferies Financial Group analyst E. Yang now forecasts that the company will post earnings per share of ($2.14) for the []

Generation Bio Co. (NASDAQ:GBIO) Research analysts at Wedbush cut their FY2021 EPS estimates for shares of Generation Bio in a note issued to investors on Thursday, November 11th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($2.11) per share for the year, down from their previous forecast of ($2.07). Wedbush also []

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce

CAMBRIDGE, Mass., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today an

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geof

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geof

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff

Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model